

-
- cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation* 2003; 107: 1401-1406.
45. Gosse P, Lasserre R, Minifie C *et al.* Blood pressure surge on rising. *J Hypertens* 2004; 22: 1113-1118.
 46. Arntz HR, Willich SN, Schreiber C *et al.* Diurnal, weekly and seasonal variation of sudden death. Population-based analysis of 24,061 consecutive cases. *Eur Heart J* 2000; 21: 315-320.
 47. Murakami S, Otsuka K, Kubo Y *et al.* Repeated ambulatory monitoring reveals a Monday morning surge in blood pressure in a community-dwelling population. *Am J Hypertens* 2004; 17: 1179-1183.
 48. Kuwajima I, Mitani K, Miyao M *et al.* Cardiac implications of the morning surge in blood pressure in elderly hypertensive patients: relation to arising time. *Am J Hypertens* 1995; 8: 29-33.
 49. Marfella R, Gualdiero P, Siniscalchi M *et al.* Morning blood pressure peak, QT intervals, and sympathetic activity in hypertensive patients. *Hypertension* 2003; 41: 237-243.
 50. Caramori ML, Pecis M, Azevedo MJ. Increase in nocturnal blood pressure and progression to microalbuminuria in diabetes. *N Engl J Med* 2003; 348: 260-264.
 51. Kamoi K, Miyakoshi M, Soda S *et al.* Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. *Diabetes Care* 2002; 25: 2218-2223.
 52. Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. *Stroke* 2003; 34: 2471-2474.
 53. Eguchi K, Kario K, Hoshida S *et al.* Type 2 diabetes is associated with LV concentric remodeling in hypertensive patients. *Am J Hypertens* 2005; 18: 23-29.
 54. Lurbe E, Redon J, Kesani A *et al.* Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. *N Engl J Med* 2002; 347: 797-805.
 55. Nakano S, Fukuda M, Hotta F *et al.* Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. *Diabetes* 1998; 47: 1501-1506.
 56. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. *N Engl J Med* 1991; 325: 986-990.
 57. Kario K, Pickering TG, Hoshida S *et al.* Morning blood pressure surge and hypertensive cerebrovascular disease: role of the α -adrenergic sympathetic nervous system. *Am J Hypertens* 2004; 17: 668-675.
 58. Otto ME, Svatikova A, Barretto RB *et al.* Early morning attenuation of endothelial function in healthy humans. *Circulation* 2004; 109: 2507-2510.
 59. Andrews NP, Gralnick HR, Merryman P *et al.* Mechanisms underlying the morning increase in platelet aggregation: a flow cytometry study. *J Am Coll Cardiol* 1996; 28: 1789-1795.
 60. Ikeda Y, Handa M, Kawano K *et al.* The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. *J Clin Invest* 1991; 87: 1234-1240.
 61. Kapiotis S, Jilma B, Quehenberger P *et al.* Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. *Circulation* 1997; 96: 19-21.
 62. Maemura K, de la Monte SM, Chin MT *et al.* CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. *J Biol Chem* 2000; 275: 36847-36851.
 63. Ridker PM, Gaboury CL, Conlin PR *et al.* Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the reninangiotensin system and fibrinolytic function. *Circulation* 1993; 87: 1969-1973.
 64. Kario K, Matsuo T, Kobayashi H *et al.* Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. *Arterioscler Thromb Vasc Biol* 1995; 15: 1114-1120.
 65. Kario K, Matsuo T, Kobayashi H *et al.* Hyperinsulinemia and hemostatic abnormalities are associated with silent cerebral lacunar infarcts in elderly hypertensive subjects. *J Am Coll Cardiol* 2001; 37: 871-877.
 66. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. *Nature* 2002; 418: 935-941.
 67. Nonaka H, Emoto N, Ikeda K *et al.* Angiotensin II induces circadian gene expression of clock genes in
-

- cultured vascular smooth muscle cells. *Circulation* 2001; 104: 1746-1748.
68. Kario K, Matsuo T, Shimada K *et al.* Factors associated with the occurrence and magnitude of earthquake-induced increases in blood pressure. *Am J Med* 2001; 111: 379-384.
69. Kario K. Management of high casual blood pressure in a disaster situation: The 1995 Hanshin-Awaji earthquake. *Am J Hypertens* 1998; 11: 1138-1139.
70. Kario K, Matsuo T, Kobayashi H *et al.* Earthquake-induced potentiation of acute risk factors in hypertensive patients: possible triggering of cardiovascular events after a major earthquake. *J Am Coll Cardiol* 1997; 29: 926-933.
71. Imai Y, Nagai K, Sakuma M *et al.* Ambulatory blood pressure of adults in Ohasama, Japan. *Hypertension* 1993; 22: 900-912.
72. Kario K, Eguchi K, Umeda Y *et al.* Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Response. *Circulation* 2003; 108: 72e-73e.
73. Kario K, Eguchi K, Umeda Y *et al.* Morning blood pressure surge and the risk of stroke. *Circulation* 2003; 108: 110e-111e.
74. Redon J, Roca-Cusachs A, Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Analysis of the Control of Blood Pressure using Ambulatory Blood Pressure Monitoring. *Blood Press Monit* 2002; 7: 111-116.
75. Pickering TG, Kaplan NM, Krakoff L *et al.*; for the American Society of Hypertension Expert Panel. Conclusions and recommendations on the clinical use of home(self) and ambulatory blood pressure monitoring. *Am J Hypertens* 1996; 9: 1-11.
76. Chobanian AV, Bakris GL, Black HR *et al.*; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; 42: 1206-1252.
77. Kuroda T, Kario K, Shimada K. Morning hypertension and cardiac remodeling in treated hypertensive patients. (Personal communication.)
78. Ikeda T, Yamamoto K, Okada J *et al.* Morning rise in blood pressure associates with hypertensive cardiovascular complications. *J Hypertens* 2002; 20(Suppl 4): S150.
79. Kario K. Time to focus on morning hypertension. Pitfalls of current antihypertensive medication. *Am J Hypertens* 2004; 17: 1075-1076.
80. Kario K, Yasui N, Yokoi H. Ambulatory blood pressure monitoring for cardiovascular medicine. Evaluating blood pressure behavior outside of the clinical setting and during daily activities to identify high-risk subjects. *IEEE Eng Med Biol Mag* 2003; 22: 81-88.
81. White WB. Ambulatory blood-pressure monitoring in clinical practice. *N Engl J Med* 2003; 348: 2377-2378.
82. Kario K. Blood pressure variability in hypertension. A possible cardiovascular risk factor. *Am J Hypertens* 2004; 17: 1075-1076.
83. Kario K, Pickering TG. Blood pressure variability in elderly patients. *Lancet* 2000; 355: 1645-1646.
84. Kario K, Eguchi K, Hoshida S *et al.* U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. *J Am Coll Cardiol* 2002; 40: 133-141.
85. Pickering TG, Davidson K, Gerin W *et al.* Masked hypertension. *Hypertension* 2002; 40: 795-796.
86. Bjorklund K, Lind L, Zethelius B *et al.* Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. *Circulation* 2003; 107: 1297-1302.
87. Bobrie G, Chatellier G, Genes N *et al.* Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA* 2004; 291: 1342-1349.
88. Clement DL, De Buyzere ML, De Bacquer DA *et al.* Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated

-
- hypertension. *N Engl J Med* 2003; 348: 2407-2415.
89. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. *Circulation* 1999; 100: 1635-1638.
 90. Eguchi K, Kario K, Hoshida Y *et al.* Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. *Am J Hypertens* 2004; 17: 112-117.
 91. Kitahara Y, Saito F, Akao M *et al.* Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients. *J Cardiovasc Pharmacol* 2004; 43: 68-73.
 92. Wellington K, Scott LJ. Azelnidipine. *Drugs* 2003; 63: 2613-2621.
 93. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group. *Am J Hypertens* 1994; 7: 848-852.
 94. Pickering TG, Levenstein M, Walmsley P. Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. *Am J Hypertens* 1994; 7: 844-847.
 95. Naito Y, Tsujino T, Fujioka Y *et al.* Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. *Hypertension* 2002; 40: 827-833.
 96. Kuroda T, Kario K, Hoshida S *et al.* Effects of bedtime vs. morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients. *Hypertens Res* 2004; 27: 15-20.
 97. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet* 2000; 355: 253-259.
 98. Svensson P, de Faire U, Sleight P *et al.* Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. *Hypertension* 2001; 38: E28-E32.
 99. Dahlof B, Devereux RB, Kjeldsen SE *et al.*; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359: 995-1003.
 100. Lithell H, Hansson L, Skoog I *et al.*; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 2003; 21: 875-886.
 101. Pfeffer MA, Swedberg K, Granger CB *et al.*; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 2003; 362: 759-766.
 102. Julius S, Kjeldsen SE, Weber M *et al.*; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004; 363: 2022-2031.
 103. Kario K, Pickering TG. VALUE: analysis of results. *Lancet* 2004; 364: 934.
 104. Burnier M, Brunner HR. Angiotensin II receptor antagonists. *Lancet* 2000; 355: 637-645.
 105. Eguchi K, Kario K, Shimada K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. *Am J Cardiol* 2003; 92: 621-624.
 106. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. *Am J Hypertens* 2004; 17: 347-353.
 107. Smith DHG, Cramer M-JM, Neutel J *et al.* Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. *Blood Press Monit* 2003; 8: 111-117.
 108. Lacourciere Y, Gil-Extremera B, Mueller O *et al.* Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. *Int J*
-

- Clin Pract* 2003; 57: 273-279.
109. Neutel J, Chrysant SG, Littlejohn TW. Telmisartan 40 or 80mg/HCT 12.5mg fixed dose combinations provide superior BP reductions compared to losartan 50mg/HCT12.5mg fixed dose combination during the last 6 hours of the dosing interval: an ABPM comparison. 19th Annual Scientific Meeting of the American Society of Hypertension, New York. *Am J Hypertens* 2004.
 110. Lacourciere Y, Krzesinski JM, White WB *et al.* Sustained antihypertensive activity of telmisartan compared with valsartan. *Blood Press Monit* 2004; 9: 203-210.
 111. Lacourciere Y, Lenis J, Orchard R *et al.*; on behalf the Canadian Telmisartan Study Group. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. *Blood Press Monit* 1998; 3: 295-302.
 112. Ragot S, Ezzaher A, Meunier A *et al.* Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVEREST study. *J Hum Hypertens* 2002; 16: 865-873.
 113. Lacourciere Y, Neutel J, Koval SE *et al.* A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. 9th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research (ECCR), Nice. 1.3 October 2004. *Hypertension* 2004; 44: 576.
 114. Williams B, Grosse P, Lowe L *et al.* Superior BP reduction in the last 6 h of the dosing interval with once-daily telmisartan vs ramipril. 9th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research (ECCR), Nice. 1.3 October 2004. *Hypertension* 2004; 44: 576.
 115. Benson SC, Pershadsingh HA, Ho CI *et al.* Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. *Hypertension* 2004; 43: 993-1002.
 116. Schupp M, Janke J, Clasen R *et al.* Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor gamma activity. *Circulation* 2004; 109: 2054-2057.
 117. Rosano GM, Vitale C, Castiglioni A *et al.* Comparative effects of telmisartan and losartan on glucose metabolism in hypertensive patients with metabolic syndrome. American Heart Association Scientific Sessions 2004. New Orleans, USA. *Circulation* 2004.
 118. Derosa G, Cicero AFG, Bertone G *et al.* Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. *Clin Ther* 2004; 26: 1228-1236.
 119. Derosa G, Ragonesi PD, Mugellini A *et al.* Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. *Hypertens Res* 2004; 27: 457-464.
 120. Weber M. The telmisartan Programme of Research to show Telmisartan End-organ protection potential (PROTECTION) programme. *J Hypertens* 2003; 21 (Suppl 6): S37-S46.
 121. Nakagawa H, Morikawa Y, Okayama A *et al.* Trends in blood pressure and urinary sodium and potassium excretion in Japan: reinvestigation in the 8th year after the intersalt Study. *J Hum Hypertens* 1999; 13: 735-741.
 122. Teo K, Yusuf S, Anderson C *et al.*; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) trials. *Am Heart J* 2004; 148: 52-61.
 123. The PROfESS Collaborative Group. The largest stroke trial ever to investigate the prevention of recurrent stroke 15,500 patients from up to 600 centers and 26 countries worldwide during 2003-2007. 29th International Stroke Conference, San Diego California, 5-7 February 2004.

著者略歴

刈尾 七臣 (かりお かずおみ)

1962年兵庫県龍野市に生まれる。1987年自治医科大学医学部卒業。兵庫県立尼崎病院研修後、1989年兵庫県淡路島国保北淡診療所勤務。1996年自治医科大学循環器内科学講座助手。1998年～2000年米国コーネル大学医学部循環器センター、米国ロックフェラー大学ゲスト・インベスティゲータ。1999年より米国国立衛生院プログラムプロジェクト共同研究員。2000年自治医科大学内科学講座循環器内科学部門講師、米国マウントサイナイ医科大学循環器センター客員助教授を経て、2005年より自治医科大学Center of Excellence (COE) /内科学講座循環器内科学部門教授。米国コロンビア大学医学部内科客員教授（兼任）。



現在、日本循環器学会専門医、日本心臓病学会フェロー、日本高血圧学会評議員およびフェロー、米国心臓病学会フェロー (FACC)、米国内科学会フェロー (FACP)、米国心臓病協会高血圧研究部会フェロー (FAHA)。日本高血圧学会誌の編集幹事、日本循環器学会誌や米国心臓病学会誌、米国高血圧学会誌等、国際学術10雑誌の編集委員を務める。

他に、1997年自治医科大学研究奨励賞、1999年米国高血圧学会（ニューヨーク州）若手研究奨励賞、2001年日本心臓病学会若手研究奨励賞、2001年日本高血圧学会若手研究奨励賞、2003年日本内科学会若手研究奨励賞、2004年日本心臓病学会臨床研究最優秀論文賞、2005年米国高血圧学会シンポジウム賞を受賞。主な専門・研究分野は循環器内科学、高血圧、血栓症。

Type 2 Diabetes Is Associated With Left Ventricular Concentric Remodeling in Hypertensive Patients

Kazuo Eguchi, Kazuomi Kario, Satoshi Hoshide, Joji Ishikawa, Masato Morinari, and Kazuyuki Shimada

Background: Left ventricular (LV) geometric remodeling is associated with cardiovascular prognosis in hypertensive patients. It is uncertain how LV remodeling is modulated by diabetes in hypertensive patients. In this study, we investigated the impact of diabetes and ambulatory blood pressure (BP) on LV geometric remodeling in hypertensives with/without diabetes.

Methods: Ambulatory BP monitoring and echocardiography were performed to compare 24-h BP levels and LV measurements in 400 uncomplicated hypertensives (mean age, 67 years, 152 men and 248 women) between diabetic ($n = 161$) and nondiabetic ($n = 239$) patients.

Results: The age (67 v 68 years), percentage of men (43% v 34%), body mass index (24.5 v 24.0 kg/m²), 24-h systolic BP (144/80 v 144/82 mm Hg), LV mass index (128 v 130 g/m²) were similar between the groups. Diabetic patients had higher relative wall thickness (0.50 v

0.44 , $P < .001$) and higher prevalence of concentric LV hypertrophy (39.4% v 26.8%, $P < .001$) than nondiabetic patients. The presence of diabetes (odds ratio [OR] = 2.76; 95% confidence interval [CI] = 1.73–4.41, $P < .001$) and 24-h systolic BP (OR for 10 mm Hg increase = 1.17; 95% CI = 1.01–1.37, $P < .05$) were independently associated with the higher relative wall thickness (≥ 0.45). On the other hand, 24-h systolic BP was independently associated with LV hypertrophy (OR for 10 mm Hg increase = 1.32; 95% CI = 1.14–1.52, $P < .05$).

Conclusions: Among hypertensive patients, type 2 diabetes was associated with concentric LV geometry independent of ambulatory BP. *Am J Hypertens* 2005;18: 23–29 © 2005 American Journal of Hypertension, Ltd.

Key Words: Type 2 diabetes, hypertension, concentric hypertrophy, left ventricular geometric remodeling, ambulatory blood pressure monitoring.

Diabetes mellitus is one of the most important risk factors for cardiovascular disease.¹ Diabetes mellitus and hypertension frequently coexist and each pathologic condition exacerbates the other.² Several population studies have shown that diabetes is associated with left ventricular (LV) structural and functional abnormalities.^{3–5} In the Hypertension genetic epidemiology network (HyperGEN) study⁴ and the Strong Heart Study,⁵ type 2 diabetes was associated with higher LV mass, more concentric LV geometry, and lower cardiac function. Because there is a strong relationship between LV hypertrophy and adverse cardiovascular outcomes in hypertensive patients,^{6–8} early detection of LV structural changes in diabetic patients may be important.

The level of blood pressure (BP) using ambulatory BP monitoring correlates better than clinic BP measurements with hypertensive target organ damage.⁹ Patients with white coat hypertension, defined as persistent clinic hypertension but normal 24-h BP with ambulatory BP monitoring, have smaller LV mass than patients with sustained hypertension. The LV mass of the former is similar to that of normotensive patients.¹⁰ Although diabetes and hypertension both may be contributing factors to LV remodeling, there are few reports showing the impact of ambulatory BP on LV remodeling in diabetic patients.

Thus we performed a cross-sectional study to assess the association of diabetes and ambulatory BP with LV geometric remodeling in Japanese hypertensive patients with and without diabetes.

Received January 13, 2004. First decision August 27, 2004. Accepted August 28, 2004.

From the Department of Cardiology, Shioya General Hospital, Tochigi, Japan (KE), and the Department of Cardiology, Jichi Medical School (KE, KK, SH, JI, MM, KS), Tochigi-Ken, Japan.

Address correspondence and reprint requests to Dr. Kazuo Eguchi, Jichi Medical School, Department of Cardiology, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0490 Japan; e-mail: Kazuo-eg@jichi.ac.jp

Methods

Patients

We studied 400 essential hypertensive patients (mean age, 68 ± 9 years; range, 41 to 88 years; 152 men and 248 women), composed of 161 patients diagnosed with diabetic hypertension (diabetic group) and 239 with nondiabetic hypertension (nondiabetic group). We enrolled hypertensive outpatients into our study from three participating institutes (one clinic, two hospitals). Hypertensive patients were consecutively selected according to the following criteria: 1) essential hypertension with average clinic systolic BP >140 mm Hg or average clinic diastolic BP of >90 mm Hg (average for each patient on two or more occasions) if not medicated;¹¹ 2) taking antihypertensive medication because of hypertension; and 3) aged ≥ 40 years old. No patient had taken any antihypertensive medication for at least 1 week before the ambulatory BP monitoring. None of the patients were hospitalized during the study period. We excluded patients with renal failure (serum creatinine ≥ 132.6 mmol/L), hepatic damage, secondary or malignant hypertension, symptomatic ischemic heart disease or other cardiac disease, congestive heart failure, arrhythmias including atrial fibrillation, stroke (including transient ischemic attacks), or other severe concomitant disease.

Diabetes mellitus was defined according to the criteria of the American Diabetes Association.¹² All of the diabetic patients had type 2 diabetes mellitus. Body mass index (BMI) was calculated as weight (in kilograms)/height (in meters squared). The HbA_{1C} data were calculated as an average of the recent 5 years of HbA_{1C} if there were more than 5 years of data for each patient. If there were less than 5 years of HbA_{1C} data, we used all of the HbA_{1C} data available to calculate the average HbA_{1C}. This study was approved by the Research Ethics Committee, Department of Cardiology, Jichi Medical School, Jichi, Japan. All of the patients gave informed consent for this study.

Echocardiographic Measurements and Calculation

M-mode echocardiography, guided by a two-dimensional echocardiography, was performed with the patient maintained in a partial left decubitus position.

Echocardiographic tracings were performed by one physician using the same procedure in a blinded manner at all three centers. Standardization of tracing was performed in the same manner at all three institutes. The LV internal dimension, interventricular septal thickness, and posterior wall thickness were measured at end-diastole and end-systole according to the American Society of Echocardiography (ASE) recommendations.¹³ When optimal orientation of the M-mode line could not be obtained, correctly oriented leading edge linear dimension measurements were made from two-dimensional images according to ASE recommendations.¹⁴ The measurements were per-

formed within 3 months before the ambulatory BP monitoring and made in a blinded manner.

End-diastolic LV dimensions were used to calculate LV mass using an anatomically validated formula described previously.¹⁵ The LV mass index (LVMI) was calculated for each patient by dividing LV mass by body surface area (BSA). Relative wall thickness (RWT) was calculated as twice the posterior wall thickness divided by the end-diastolic LV dimension. End-diastolic and end-systolic LV volumes were calculated by the Teichholz method. Linear measurement-derived ejection fraction was calculated as the percentage reduction of LV volume from end-diastole to end-systole. The presence of LV hypertrophy (LVH) was defined by sex-specific criteria (LVMI ≥ 110 g/m² in women and ≥ 134 g/m² in men) as described previously.¹⁶

Reproducibility

Twenty LV mass and RWT measurements were performed by one observer at two separate times for determination of intraobserver variabilities. The results were expressed as a linear regression between the two measurements and as a percent error that was derived as 100 times the absolute difference between measurements divided by the initial measurements. The intraobserver correlation coefficient and the percent error of LV mass was 0.91 and $0.39\% \pm 12.9\%$, and that of RWT was 0.92 and $3.99\% \pm 9.2\%$, respectively.

24-h Ambulatory BP Monitoring

Noninvasive ambulatory BP monitoring was carried out on a weekday with an automatic system using electric-powered cuff inflation (TM2421, A&D, Tokyo, Japan), which recorded both BP (by the oscillometric method) and pulse rate every 30 min for 24 h. The same ambulatory BP monitoring device was used at the three centers and the data were analyzed by the same method. The accuracy of this device was previously validated. Sleep BP was defined as the average of BP measurements from the time when the patient went to bed until the time he/she got out of bed; and awake BP, as the average of BP measurements recorded during the rest of the day. Nondipper was defined as sleep systolic BP/awake systolic BP ratio >0.90 . Sustained hypertension (SHT) and white coat hypertension (WCHT) were defined as follows: clinic BP $>140/90$ mm Hg (either) and 24-h BP $\geq 135/80$ (either) mm Hg for SHT; clinic BP $>140/90$ mm Hg (either) and 24-h BP $<135/80$ mm Hg (both) for WCHT.

Statistical Analysis

All statistical analyses were carried out with SPSS/Windows, version 11.0J (SPSS Inc., Chicago, IL). The χ^2 test was used to calculate proportions (Tables 1 to 4). Unpaired *t* tests or one-way analysis of variance was performed to detect differences of mean values between the diabetic and nondiabetic group (Tables 1 to 4). Tukey's honestly significant difference test was used for multiple comparisons of variables between two of four groups (WCHT + diabetes, WCHT + nondiabetes, SHT + diabetes, and SHT + nondiabetes) (Table 3).

Table 1. Baseline characteristics of 400 diabetic or nondiabetic patients

	Diabetic Group (n = 161)	Nondiabetic Group (n = 239)	P
Age (years)	67 ± 9	68 ± 9	.09
Male gender (%)	70 (43)	82 (34)	.07
Body Mass Index (kg/m ²)	25 ± 4	24 ± 3	.15
Height (cm)	155 ± 9	153 ± 9	.04
Weight (kg)	59.0 ± 12	56.3 ± 10	.015
Smoker (%)	46 (29)	67 (28)	.9
Hematocrit (%)	40 ± 5	40 ± 4	.1
Duration of hypertension (y)	9 ± 9	7 ± 6	.03
Duration of diabetes (y)	11 ± 8	ND	
Hemoglobin A _{1c} (%)	7.35 ± 1.1	ND	
Total cholesterol (mmol/L)	5.30 ± 0.85	5.35 ± 0.91	.4
Triglyceride (mmol/L)	1.61 ± 0.86	1.34 ± 0.60	.001
Serum creatinine (mmol/L)	70.7 ± 35.4	70.7 ± 17.7	.2
Clinic SBP (mm Hg)	155 ± 17	164 ± 16	<.001
Clinic DBP (mm Hg)	82 ± 10	89 ± 12	<.001
24-h SBP (mm Hg)	144 ± 17	144 ± 15	.8
24-h DBP (mm Hg)	80 ± 9	82 ± 9	.04
24-h PR (beats/min)	70 ± 9	67 ± 8	.002
Awake SBP (mm Hg)	149 ± 17	151 ± 15	.4
Awake DBP (mm Hg)	83 ± 9	86 ± 10	.01
Awake PR (beats/min)	74 ± 9	71 ± 9	.01
Sleep SBP (mm Hg)	135 ± 19	132 ± 17	.08
Sleep DBP (mm Hg)	74 ± 10	75 ± 10	.4
Sleep PR (beats/min)	63 ± 9	60 ± 8	<.001
Sleep:awake BP ratio	0.91 ± 0.1	0.88 ± 0.1	<.001
Nondipper (%)	86 (53)	102 (43)	.04

Data are number (%) or mean ± SD. Overall P values are shown for two-group comparison of means (unpaired t test) or percentages (χ^2 test).

BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; PR = pulse rate, ND = No data.

Spearman's correlation was used for bivariate analyses between 24-h systolic BP and LVMI and RWT, and between LVMI and RWT. Odds ratios (OR) with 95% confidence intervals (CI) for no or some LVH (0 = those with no LVH; 1 = those with LVH criteria) and for RWT (0 = those with RWT <0.45; 1 = those with RWT ≥0.45) were calculated

using multiple logistic regression analysis using the following selected independent variables for cardiovascular risk: age, gender (0 = women, 1 = men), BMI, duration of hypertension, smoking (0 = absent, 1 = present), presence of diabetes (0 = absent, 1 = present), 24-h systolic BP, serum creatinine, total cholesterol, and use of antihypertensive med-

Table 2. Comparison of echocardiographic parameters between diabetic and nondiabetic patients

	Diabetic Group (n = 161)	Nondiabetic Group (n = 239)	P
LV mass index (g/m ²)	129 ± 35	130 ± 34	.7
LV mass / height ^{2.7}	61.4 ± 17	64.1 ± 19	.166
Relative wall thickness	0.50 ± 0.1	0.44 ± 0.1	<.001
Interventricular septal thickness (mm)	10.9 ± 1.5	10.3 ± 1.8	<.001
Posterior wall thickness (mm)	10.9 ± 1.5	10.2 ± 1.6	<.001
LV internal dimension at end-diastole (mm)	44 ± 6	47 ± 5	.03
LV internal dimension at end-systole (mm)	28 ± 5	29 ± 5	<.001
Ejection fraction (%)	72 ± 7	75 ± 6	<.001
Geometric pattern			
Normal pattern (%)	26 (16)	60 (25)	.04
Concentric remodeling (%)	46 (29)	29 (12)	<.001
Concentric hypertrophy (%)	63 (39)	64 (27)	.01
Eccentric hypertrophy (%)	26 (16)	86 (36)	<.001

Data are number (%) or mean ± SD. Overall P values are shown for two-group comparison of means (unpaired t test) or percentages (χ^2 test).

Table 3. Comparison of RWT and LVMI between diabetic and nondiabetic patients

	White Coat Hypertension		Sustained Hypertension	
	Diabetic Group	Nondiabetic Group	Diabetic Group	Nondiabetic Group
<i>n</i>	44	71	117	168
Age (y)	66 ± 9	68 ± 9	67 ± 9	69 ± 9
Male gender (%)	43	35	44	34
LVIDd (mm)	44 ± 6*	47 ± 5	44 ± 6†	47 ± 5
IVS (mm)	10.4 ± 1.2	10.0 ± 1.7	11.1 ± 1.6†	10.4 ± 1.9
PWT (mm)	10.3 ± 1.3	9.9 ± 1.5	11.1 ± 1.5†	10.4 ± 1.7
24-hr systolic BP (mm Hg)	126 ± 7	127 ± 6	151 ± 14	151 ± 11
LV mass index (g/m ²)	118 ± 31	124 ± 31	133 ± 36	132 ± 36
LV mass/height ^{2.7}	55.2 ± 15	60.4 ± 15	63.8 ± 18§	65.6 ± 21§
Relative wall thickness (%)	0.47 ± 0.1*	0.42 ± 0.1	0.51 ± 0.1‡	0.45 ± 0.1
	12 (27)	13 (18)	52 (44)*	52 (30)

LVIDd = LV internal dimension at end-diastole; IVS = interventricular septal thickness; PWT = posterior wall thickness.

Data are number (%) or mean ± SD.

* $P < .05$, † $P < .01$, ‡ $P < .001$ v nondiabetic group; § $P < .05$ v diabetic white coat hypertension.

ications (0 = absent, 1 = present). A two-sided P value < .05 was considered statistically significant.

Results

Clinical Characteristics of the Patients

The mean ± SD clinic BP of the overall study group was 157 ± 20 mm Hg systolic and 85 ± 13 mm Hg diastolic, and 24-h BP was 142 ± 16 mm Hg systolic and 80 ± 9 mm Hg diastolic. The prevalence of LVH was 56% and that of RWT ≥ 0.45 was 50% in the overall study group.

Table 1 shows the characteristics of the 400 hypertensive patients separated into the diabetic group ($n = 161$) and nondiabetic group ($n = 239$). The age, gender, BMI, smoker, hematocrit, total cholesterol, serum creatinine, and 24-h systolic BP were similar between the groups. However, duration of hypertension, triglycerides, 24-h pulse rates, and sleep/awake BP ratio were significantly higher in the diabetic group than in the nondiabetic group. The clinic systolic BP/diastolic BP, 24-h diastolic BP, and awake diastolic BP were significantly lower in the diabetic group than in the nondiabetic group.

Table 4. Comparison of taking antihypertensives, insulin, and oral hypoglycemics

	Diabetic Group (<i>n</i> = 161)	Nondiabetic Group (<i>n</i> = 239)	<i>P</i>
% Taking antihypertensives	121 (75)	168 (70)	.307
Calcium channel blockers	80 (50)	119 (50)	1.000
ACE inhibitors	50 (31)	32 (13)	<.001
Angiotensin 1 receptor blockers	41 (25)	23 (10)	<.001
Diuretics	32 (20)	24 (10)	.008
β blockers	9 (6)	10 (4)	.633
α ₁ blockers	5 (3)	1 (0)	.041
Numbers taking antihypertensives	1.4 ± 1.0	0.9 ± 0.8	<.001
% Taking insulin	45 (28)	0	<.001
% Taking oral hypoglycemics	102 (63)	0	<.001
% Taking sulfonylureas	62 (39)	0	<.001
% Taking metformin	33 (20)	0	<.001
% Taking α-glucosidase inhibitors	48 (30)	0	<.001
% Taking aldose reductase inhibitor	14 (9.0)	0	<.001
% Taking pioglitazone	4 (2.5)	0	.026
Numbers taking oral hypoglycemics			
0	44 (27)	0	<.001
1	49 (30)	0	<.001
2	47 (29)	0	<.001
3	21 (13)	0	<.001

Data are number (%) or mean ± SD. Overall P values for two-group comparison of means (unpaired t test) or percentages (χ^2 test).




FIG. 1 Characteristics of the LV geometric remodeling pattern in each group. The average values of left ventricular mass index and relative wall thickness were plotted for each group. SHT = sustained hypertension (24-h systolic BP \geq 135 mm Hg); WCHT = white coat hypertension (24-h systolic BP $<$ 135 mm Hg); DM = diabetes mellitus. Each average 24-h BP value is indicated between parentheses.

LV Mass and LV Geometry

As shown in Table 2, LVMI and LV mass/height^{2.7} were similar between the diabetic group and nondiabetic group, but RWT was significantly higher in the diabetic group than in the nondiabetic group. Twenty-four-hour BP was significantly associated with LVMI and RWT in both the diabetic group ($r = 0.33, P < .001$) and nondiabetic group ($r = 0.23, P < .001$). There were significant positive relationships between LVMI and RWT in the nondiabetic group ($r = 0.27, P < .001$), but no relationship was found in the diabetic group ($r = 0.05, P = .51$). In our population, there were only 10 patients with a BMI more than 30 kg/m² in the diabetic group (6.2%) and only 8 in the nondiabetic group (3.3%). Therefore, LV mass corrected by BSA would not underestimate the deviation from normal due to body size variation within the two groups.

As shown in Table 3, age, gender, 24-h BP, and LV mass were not significantly different between the diabetic

group and nondiabetic group within the same group of WCHT or SHT. The RWT was greater in the diabetic group than in the nondiabetic group. Although the prevalence of concentric LV hypertrophy was higher in the diabetic group than in the nondiabetic group only in the SHT group, it was not different between the WCHT and SHT groups within the diabetic group or nondiabetic group. We plotted the mean value of LVMI and RWT in each of the four groups and showed that 24-h systolic BP was associated with LVMI and presence of diabetes was associated with RWT (Fig. 1).

Table 4 shows the antihypertensive medication status and antidiabetic drugs used in this study. Although there were no significant differences in the rate of antihypertensive medication, the percentage taking angiotensin-converting enzyme (ACE) inhibitors, angiotensin type 1 receptor blockers (ARBs), and diuretics was significantly higher among diabetics than among nondiabetics.

By multiple logistic regression analysis, LVH was only associated with 24-h BP. However, higher RWT (≥ 0.45) was associated both with presence of diabetes and 24-h systolic BP (Table 5). To assess the effect of antihypertensive medication, we added antihypertensive medication status (0 = absent, 1 = present at examination), calcium channel blockers (CCBs), ACE inhibitors, ARBs, and diuretics (0 = absent, 1 = present before examination) to the model shown in Table 5, but the results were not significantly changed and only ACE inhibitor use was associated with relative wall thickness.

Discussion

In this cross-sectional study, we examined the impact of diabetes and ambulatory BP on LV structure in hypertensive patients. We found associations of type 2 diabetes with higher RWT and higher prevalence of concentric hypertrophy independent of ambulatory BP. In contrast to

Table 5. Determinants of LV hypertrophy and relative wall thickness ≥ 0.45 in overall patients

	Presence of LV Hypertrophy	Relative Wall Thickness ≥ 0.45
Age (10 y)	1.27 (0.99–1.64)	1.39 (1.06–1.81)*
Male gender	0.75 (0.46–1.21)	2.02 (1.23–3.32)†
Body mass index (kg/m ²)	1.04 (0.98–1.11)	1.02 (0.95–1.08)
Presence of diabetes	0.69 (0.44–1.09)	2.76 (1.73–4.41)†
24-h SBP (10 mm Hg)	1.32 (1.14–1.52)*	1.17 (1.01–1.37)*
Cholesterol (mg/dL)	1.00 (0.99–1.01)	1.00 (1.00–1.01)
Creatinine (mg/dL)	1.42 (0.65–3.14)	0.86 (0.43–1.74)
CCBs	0.74 (0.48–1.14)	0.96 (0.61–1.49)
ACE inhibitors	1.43 (0.81–2.53)	2.43 (1.35–4.38)†
ARBs	1.24 (0.66–2.34)	1.34 (0.70–2.53)
Diuretics	1.15 (0.59–2.22)	1.76 (0.89–3.50)

Data are shown as odds ratio (95% confidence Interval).

SBP = systolic BP; CCB = calcium channel blocker; ACE = angiotensin-converting enzyme; ARB = angiotensin type 1 receptor blocker. Gender was coded as male = 1, female = 0; antihypertensive drugs were coded as 1 = present, 0 = absent.

* $P < .05$, † $P < .001$.

the findings of previous reports,^{4,5} LVMI was not increased in the diabetic group compared to the nondiabetic group. There was an association between treatment with ACE inhibitors and concentric LV geometry, possibly because there was a significantly higher percentage of ACE inhibitor users among diabetics. Echocardiographically determined LV mass and geometry are clinically important to stratify the risk in essential hypertension.¹⁷ In a recent study, oxygen utilization of myocardium was lowered in concentric hypertrophy,¹⁸ and concentric hypertrophy has been identified as having the worst cardiovascular prognosis.^{6–8}

The reason LV mass did not differ between the diabetic group and nondiabetic group may be because there were no significant differences in BMI between the groups. Obesity, along with insulin resistance, directly promotes myocardial hypertrophy and is a strong determinant of LVH.^{19–21} In our population, average BMI was similar between the diabetic group and nondiabetic group. This may also contribute to explaining the fact that diabetic patients did not have larger LV internal diameter as compared to nondiabetic hypertensive subjects. Therefore, our population was appropriate for analysis of the association of LV mass and LV geometric remodeling independent of BMI. Ethnicity can be a contributing factor to explaining the differences in the cardiovascular phenotype.²² In many previous reports, BMI in Japanese or Chinese diabetic patients was relatively lower than that in Western populations.^{23–25} The pathogenesis of diabetes in an Asian population might be completely different from that in an American diabetic population.

In the present study, although diabetic patients clearly had thicker cardiac walls (11 v 10 mm), they did not have an increased cardiac mass (129 v 130 mg/m²) because their chambers were less dilated than those of nondiabetic patients (44 v 47 mm). After controlling for body height, LV dimension in diabetics was still significantly smaller. In previous reports, there were conflicting results about LV dimension in diabetic patients. In the report by Palmieri et al⁴ there were no differences in LV end-diastolic dimension between diabetics and nondiabetics. On the other hand, LV end-diastolic dimension in diabetics was smaller than that in controls.^{26,27}

Hypertension is the most powerful determinant of LVH. In the present study, SHT with diabetes showed the greatest RWT and prevalence of concentric hypertrophy, compared with SHT without diabetes or WCHT with diabetes. Higher ambulatory BP was a great contributor to increased LV mass, even in the diabetics. We propose the following two mechanisms: 1) LVH in diabetes depends primarily on connective tissue deposition, whereas hypertension has a greater effect on cardiocyte size.²⁸ 2) Duration of hypertension and higher peripheral resistance might play an important role in the development of concentric hypertrophy. In the Framingham study, the determinants of concentric hypertrophy were greater severity of hypertension, advancing age, and higher peripheral resis-

tance with normal intravascular volume.²⁹ In the present study, duration of hypertension was significantly greater in the diabetic group. Sympathetic nervous activation associated with insulin resistance of diabetes²⁰ or glucose resistance³⁰ might play an important role in higher peripheral vascular resistance.

The discontinuation of antihypertensive therapy might have been insufficient for ambulatory BP monitoring. However, we discontinued antihypertensive drugs for at least 1 week in all nondiabetics and most diabetics except for supposed high-risk individuals taking multiple antihypertensive drugs or having diabetic microvascular complications. Therefore, we considered the ambulatory BP values in the present study to be nearly valid ambulatory BP data. Ethically, we could not stop antihypertensive drugs for more than 1 week in high-risk individuals, and this might be a limitation of the study.

In conclusion, in a sample of Japanese hypertensive subjects, type 2 diabetes was associated with concentric LV geometry independent of ambulatory BP. In relatively lean body, diabetic hypertensive patients, LV remodeling already begins in the silent stage, which implies a high risk of future cardiovascular disease.

References

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229–234.
2. Sowers JR, Haffner S: Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. *Hypertension* 2002;40:781–788.
3. Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T: Left ventricular mass in diabetes–hypertension. *Arch Intern Med* 1992;152:1001–1004.
4. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, Kitzman DW, Hopkins PN, Morgan D, Rao DC, Devereux RB: Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: hypertension genetic epidemiology network (hyperGEN) study. *Circulation* 2001;103:102–107.
5. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV: Impact of diabetes on cardiac structure and function: the Strong Heart Study. *Circulation* 2000;101:2271–2276.
6. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. *Ann Intern Med* 1991;114:345–352.
7. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G: Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. *Circulation* 2001;104:2039–2044.
8. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C: Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. *Am J Hypertens* 2003;16:895–899.
9. Mulè G, Nardi E, Cottone S, Andronico G, Federico MR, Piazza G, Volpe V, Ferrara D, Cerasola G: Relationships between ambulatory white coat effect and left ventricular mass in arterial hypertension. *Am J Hypertens* 2003;16:498–501.

10. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A: Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. *Hypertension* 1994;24:793–801.
11. Pickering TG, for an American Society of Hypertension Ad Hoc Panel: Conclusions and recommendations on the clinical use of home (self) and ambulatory blood pressure monitoring. *Am J Hypertens* 1996;9:1–11.
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997;20:1183–1197.
13. Sahn DJ, De Maria A, Kisslo J, Weyman A: The Committee on M-mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements. *Circulation* 1978;58:1072–1083.
14. Schiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H, Gutgesell M, Reichek N, Sahn D, Schnittger I, for the American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. *J Am Soc Echocardiogr* 1989;2:358–367.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986;57:450–458.
16. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Alderman MH, Laragh JH: Standardization of M-mode echocardiographic left ventricular anatomic measurements. *J Am Coll Cardiol* 1984;4:1222–1230.
17. Martínez MA, Sancho T, Armada E, Rubio JM, Antón JL, Torre A, Palau J, Seguido P, Gallo J, Saenz I, Polo E, Torres R, Oliver J, Puig JG: Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. *Am J Hypertens* 2003;16:556–563.
18. Akinboboye OO, Chou R-L, Bergmann SR: Myocardial blood flow and efficiency in concentric and eccentric left ventricular hypertrophy. *Am J Hypertens* 2004;17:433–438.
19. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson PW, Vasan RS: Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. *Circulation* 2003;107:448–454.
20. Sasson Z, Rasooly Y, Bhesania T, Rasooly J: Insulin resistance is an important determinant of left ventricular mass in the obese. *Circulation* 1993;88:1431–1436.
21. Schillaci G, Pasqualini L, Vaudo G, Lupattelli G, Piro M, Gemelli F, De Sio M, Porcellati C, Mannarino E: Effect of body weight changes on 24-hour blood pressure and left ventricular mass in hypertension: a 4-year follow-up. *Am J Hypertens* 2003;16:634–639.
22. Hinderliter AL, Blumenthal JA, Waugh R, Chilukuri M, Sherwood A: Ethnic differences in left ventricular structure: relations to hemodynamics and diurnal blood pressure variation. *Am J Hypertens* 2004;17:43–49.
23. Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K: Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. *Diabetes* 1998;47:1501–1506.
24. Kawamura T, Umemura T, Kanai A, Uno T, Matsumae H, Sano T, Sakamoto N, Sakakibara T, Nakamura J, Hotta N: The incidence and characteristics of silent cerebral infarction in elderly diabetic patients: association with serum-soluble adhesion molecules. *Diabetologia* 1998;41:911–917.
25. Hong CY, Chia KS, Hughes K, Ling SL: Ethnic differences among Chinese, Malay and Indian patients with type 2 diabetes mellitus in Singapore. *Singapore Med J* 2004;45:154–160.
26. Airaksinen J, Ikaheimo M, Kaila J, Linnaluoto M, Takkanen J: Impaired left ventricular filling in young female diabetics. An echocardiographic study. *Acta Med Scand* 1984;216:509–516.
27. Danielsen R: Factors contributing to left ventricular diastolic dysfunction in long-term type 1 diabetic subjects. *Acta Med Scand* 1988;224:249–256.
28. Amenta F, Peleg E, Tomassoni D, Sabbatini M, Rosenthal T: Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats. *Hypertension* 2003;41:1330–1335.
29. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J 3rd, Feinleib M, Castelli WP: The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. *Circulation* 1987;75:126–133.
30. Stiefel P, Miranda ML, Rodríguez-Puras MJ, García-Morillo S, Carneado J, Pamies E, Villar J: Glucose effectiveness is strongly related to left ventricular mass in subjects with stage I hypertension or high-normal blood pressure. *Am J Hypertens* 2004;17:146–153.

Short- and Long-Term Incidence of Stroke in White-Coat Hypertension

Paolo Verdecchia, Gian Paolo Reboldi, Fabio Angeli, Giuseppe Schillaci, Joseph E. Schwartz, Thomas G. Pickering, Yutaka Imai, Takayoshi Ohkubo, Kazuomi Kario

Abstract—White-coat hypertension (WCH) has been associated with a low risk for stroke, but long-term data are scanty. We analyzed individual data from 4 prospective cohort studies from the United States, Italy, and Japan that used comparable methodology for 24-hour noninvasive ambulatory blood pressure monitoring (ABPM). Overall, 4406 subjects with essential hypertension and 1549 healthy normotensive controls who were untreated at the time of initial ABPM were followed for a median of 5.4 years up to censoring or occurrence of a first stroke. At entry, mean age of subjects was 56 years (range 18 to 97). Prevalence of WCH was 9%. During follow-up, there were 213 new cases of stroke. Stroke rate ($\times 100$ person years) was 0.35 in the normotensive group, 0.59 in the WCH group, and 0.65 in the group with ambulatory hypertension. In a multivariate analysis, the adjusted hazard ratio for stroke was 1.15 (95% confidence interval [CI], 0.61 to 2.16) in the WCH group ($P=0.66$) and 2.01 (95% CI, 1.31 to 3.08) in the ambulatory hypertension group ($P=0.001$) compared with the normotensive group. After the sixth year of follow-up, the incidence of stroke tended to increase in the WCH group, and the corresponding hazard curve crossed that of the ambulatory hypertension group by the ninth year of follow-up. In conclusion, WCH was not associated with a definitely increased risk of stroke during the total follow-up period. However, WCH might not be a benign condition for stroke in the long term. (*Hypertension*. 2005;45:203-208.)

Key Words: blood pressure monitoring, ambulatory ■ stroke ■ blood pressure

White-coat hypertension (WCH),¹ referred to as office² or isolated clinic³ hypertension, is defined by a persistently elevated clinic blood pressure (BP), with normal BP outside the hospital or doctor's office.¹⁻⁴ The prognostic significance of WCH is emerging from some event-based cohort⁵⁻⁸ and interventional⁹ studies, which suggest that individuals with WCH have a risk of major cardiovascular events apparently comparable with that of clinically normotensive subjects and markedly less than that of subjects with elevated daytime BP.

Almost all these studies examined a composite pool of cardiovascular events, so that any specific association between WCH and cerebrovascular or coronary events remains elusive. In a study from Japan,⁶ incidence of stroke was comparable between clinically normotensive individuals and subjects with WCH and increased in subjects with higher levels of ambulatory BP.⁶ However, conclusions of this study are hardly applicable to different ethnic groups at lower stroke risk.

In the present study, we pooled and analyzed individual data from 4 prospective cohort studies from the United States, Italy, and Japan that used comparable methods for 24-hour noninvasive ambulatory BP monitoring (ABPM).

Methods

The International Collaborative Study of the Prognostic Utility of ABPM was initiated to examine the relationship between ambulatory BP and the risks of cardiovascular disease using individual data from a pooled sample of large observational cohorts that contain ambulatory BP measurements. The aims of the study, the structure of the database, and all analytic and publication aspects were discussed and agreed on in advance. The study from the United States was the New York Prognostic Effects of ABPM (NYPEAP)¹⁰; the study from Italy was the Progetto Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA)^{5,11}; and the studies from Japan were the Ohasama study¹² and the Jichi Medical School (JMS)-ABPM Study, Wave 1.^{5,13} Details regarding inclusion and exclusion criteria in the single studies have been published previously.^{5,6,10-13}

The majority of subjects in the NYPEAP (83%), PIUMA (88%), and JMS-ABPM (88%) cohorts had a clinic BP ≥ 140 mm Hg systolic BP (SBP) or 90 mm Hg diastolic BP (DBP) at entry compared with only 27% in the Ohasama community sample. Subjects on antihypertensive medications in NYPEAP, PIUMA, and Tochigi, but not Ohasama, were withdrawn from medications for a minimum of 2 weeks before ABPM. In NYPEAP, PIUMA, and JMS-ABPM, clinically normotensive subjects (ie, those with office BP < 140 mm Hg SBP and 90 mm Hg DBP) were generally healthy volunteers recruited from the hospital staff or asymptomatic subjects without medical problems referred to the hospital facility for various reasons.

Received July 15, 2004; first decision July 30, 2004; revision accepted October 28, 2004.

From the Dipartimento Malattie Cardiovascolari (P.V., F.A.), Ospedale R. Silvestrini, Perugia, Italy; Dipartimento Medicina Interna (G.P.R.), Università degli Studi di Perugia, Italy; Medicina Interna (G.S.), Angiologia e Malattie da Arteriosclerosi, Università degli Studi di Perugia, Italy; Department of Psychiatry and Behavioral Science (J.E.S.), State University of New York, Stony Brook; Behavioral Cardiovascular Health and Hypertension Program PH-9 946 (T.G.P.), Columbia University College of Physicians and Surgeons, New York, NY; Department of Clinical Pharmacology and Therapeutics (Y.I., T.O.), Tohoku University Graduate School of Medicine and Pharmaceutical Science, Sendai, Japan; and Department of Cardiology (K.K.), Jichi Medical School, Tochigi, Japan.

Correspondence to Paolo Verdecchia, MD, FACC, Dipartimento Malattie Cardiovascolari, Ospedale R. Silvestrini, 06100 Perugia, Italy. E-mail verdec@tin.it

© 2005 American Heart Association, Inc.

Hypertension is available at <http://www.hypertensionaha.org>

DOI: 10.1161/01.HYP.0000151623.49780.89

Subjects with overt cardiac or cerebrovascular disease, cancer, or hepatic or renal disease at enrollment were excluded. Subjects with diabetes, defined by a fasting glucose of 7.8 mmol/L or use of an oral hypoglycemic agent or insulin, were included. All subjects provided informed consent to be included in each of the 4 studies, which were approved by local ethical committees.

BP Measurement

Details regarding the procedures for clinic BP and ABPM in the NYPEAP,¹⁰ PIUMA,^{5,11} Ohasama,¹² and JMS-ABPM^{6,13} cohorts have been published previously. Clinic BP was taken at the time of enrollment into the study. In the NYPEAP study, a BP taken by the physician was available for 85% of participants. When missing, the clinic BP taken by a nurse was substituted.

In all 4 studies, ABPM was carried out at entry. In the PIUMA study, the monitor (SpaceLabs 5200, 90202, or 90207; SpaceLabs) was set to measure BP every 15 minutes during the entire 24-hour period. In the NYPEAP study, readings were taken either: (1) every 15 minutes between 6 AM and 12 PM and at 30-minute intervals between 12 PM and 6 AM using either a Del Mar Avionics P2 or P3 or a SpaceLabs 5200 (first 672 subjects); or (2) every 15 minutes between 8 AM and 10 PM and at 30-minute intervals between 10 PM and 8 AM using a SpaceLabs 90202 monitor (last 341 subjects).

In the Ohasama study, readings were taken at 30-minute intervals. Well-trained public health nurses visited each participant on a weekday morning to attach the ABPM device and to detach it the next morning. The participants kept a diary to record daily activities. Ambulatory BP was monitored using the ABPM-630 (Nippon Colin), preset to measure BP every 30 minutes. In the JMS-ABPM, noninvasive ABPM was performed on a weekday with 1 of 3 automatic devices (ABPM-630; Nippon Colin; TM-2421 or TM-2425, A&D Co., Inc.), which recorded BP and pulse rate every 30 minutes for 24 hours.

Using self-reports of the times participants went to sleep and woke up, ambulatory BP readings were aggregated to create a mean of all readings taken while awake and the mean of all readings taken during sleep. This was done separately for SBP and DBP and for pulse pressure (PP), the difference between SBP and DBP.

White-Coat Hypertension

WCH was defined by an average awake ambulatory BP <130 mm Hg SBP and 80 mm Hg DBP. We also determined the risk of stroke associated with a definition of WCH based on an awake ambulatory BP <135/85 mm Hg.^{14,15}

Follow-Up

Follow-up was based on telephone contacts or periodical clinical visits at the referring facility or through the Regional Stroke Registration System. Stroke was defined as a focal central nervous system lesion considered vascular in origin and having clinical sequelae lasting \geq 24 hours. Fatal and nonfatal strokes were included. Transient ischemic attacks were excluded from the present analysis.

Data Analysis

Statistical analysis was performed using SPSS (SPSS) and SAS-Stat (SAS Institute). One-way ANOVA and multiple comparisons with the Tukey test when appropriate were performed to compare the study sites and the 3 groups with clinical normotension, WCH, and ambulatory hypertension. We report the number of strokes that were recorded in each study, the total number of person years of follow-up for that event, and the unadjusted incidence rate. For survival analyses, event-free curves were estimated using Kaplan-Meier product-limit method and compared by the Mantel (log-rank) test. For subjects who experienced multiple events, analysis was restricted to the first event. The independent effect of several prognostic factors on survival was tested by stepwise Cox model.¹⁶

TABLE 1. Main Characteristics in the Study Population

Variable	Total Cohort (n=5955)	NYPEAP (n=1296)	PIUMA (n=2620)	Ohasama (n=1277)	JMS-ABPM (n=762)	Overall P-Value
Age, years	56 (14)	50 (13)	51 (12)	61 (10)	72 (10)	$P<0.0001$
Ethnicity						$P<0.0001$
White, %	64.1	92.2	100	0	0	
Black, %	1.4	6.4	0	0	0	
Asian, %	34.2	0	0	100	100	
Other, %	0.3	1.4	0	0	0	
Sex, % men	50	65	53	34	38	-
Weight, kg	68.2 (16)	75.1 (14)	75.1 (14)	54.0 (9)	56 (10)	$P<0.0001$
Body mass index, kg/m ²	25.3 (3.8)	25.1 (3.5)	26.8 (3.9)	23.4 (3.0)	24.0 (3.5)	$P<0.0001$
Diabetes, %	11.0	not available	7.6	17.5	11.9	-
Cigarette smoking, %	19.7	10.7	23.6	19.3	20.9	-
Total cholesterol, mmol/L	5.43 (1.08)	5.85 (1.11)	5.54 (1.09)	4.98 (0.93)	5.17 (0.88)	$P<0.0001$
Serum creatinine, mmol/L	87.5 (22)	95.5 (23)	87.5 (21)	not available	79.6 (19)	$P<0.0001$
Serum glucose, mmol/L	5.50 (1.35)	5.81 (1.18)	5.63 (1.38)	not available	5.33 (1.39)	$P<0.0001$
Office SBP, mm Hg	149 (23)	150 (21)	154 (20)	131 (18)	160 (22)	$P<0.0001$
Office DBP, mm Hg	90 (14)	94 (11)	95 (11)	74 (11)	91 (14)	$P<0.0001$
Office PP, mm Hg	59 (17)	56 (18)	58 (17)	57 (14)	69 (16)	$P<0.0001$
Awake SBP, mm Hg	139 (17)	141 (17)	141 (16)	129 (14)	145 (18)	$P<0.0001$
Awake DBP, mm Hg	87 (15)	91 (10)	91 (11)	76 (8)	82 (29)	$P<0.0001$
Awake PP, mm Hg	52 (15)	49 (13)	50 (11)	53 (8)	62 (29)	$P<0.0001$
Sleep SBP, mm Hg	121 (18)	122 (18)	124 (17)	112 (15)	127 (18)	$P<0.0001$
Sleep DBP, mm Hg	72 (11)	76 (11)	75 (11)	64 (8)	72 (11)	$P<0.0001$
Sleep PP, mm Hg	49 (11)	46 (13)	49 (11)	48 (8)	55 (11)	$P<0.0001$

TABLE 2. Main Characteristics in the Normotensive Group and in the Groups With WCH and Ambulatory Hypertension

Variable	Normotensive Group (n=1549)	WCH (n=398)	Ambulatory Hypertension (n=4008)	Overall P-Value
Age, years	55 (14)	61 (14)*†	55 (14)	0.0001
Sex, % women	80	63†	45	0.0001
Weight, kg	60.7 (15)†	63.2 (14)*†	71.5 (15)	0.0001
Body mass index, kg/m ²	24.1 (3.4)†	24.9 (3.8)*†	25.9 (3.9)	0.0001
Diabetes, %	14.3†	11.7*†	9.5	0.0001
Cigarette smoking, %	19.9	13.9*†	20.2	0.010
Total cholesterol, mmol/L	5.11 (1.01)†	5.42 (1.07)*‡	5.55 (1.08)	0.0001
Serum creatinine, mmol/L	86.0 (19)	82.4 (17)†	87.6 (23)	0.001
Serum glucose, mmol/L	5.59 (1.40)	5.42 (1.12)	5.50 (1.36)	0.23
Office SBP, mm Hg	124 (11)†	150 (12)*†	158 (19)	0.0001
Office DBP, mm Hg	74 (9)†	86 (11)*†	96 (11)	0.0001
Office PP, mm Hg	50 (10)†	65 (16)*‡	62 (18)	0.0001
Awake SBP, mm Hg	126 (12)†	121 (6)*†	146 (15)	0.0001
Awake DBP, mm Hg	78 (21)†	73 (5)*†	92 (10)	0.0001
Awake PP, mm Hg	48(20)†	49 (6)†	54 (12)	0.0001
Sleep SBP, mm Hg	110 (13)†	110 (11)†	127 (17)	0.0001
Sleep DBP, mm Hg	64 (9)†	63 (7)†	76 (11)	0.0001
Sleep PP, mm Hg	45 (8)†	47 (8)†	51 (12)	0.0001

* $P < 0.01$ vs normotensive group; † $P < 0.01$ vs ambulatory hypertension; ‡ $P < 0.05$ vs ambulatory hypertension.

Analyses were stratified by study site because of expected differences in stroke rate between the different groups. Several potential confounding variables assessed at entry were considered in the analysis: current smoking status, weight, height, body mass index, total cholesterol, and use of antihypertensive medication, including those titrated off before ABPM. In 2-tailed tests, P values < 0.05 were considered statistically significant.

Results

Cohort Features

As shown in Table 1, age of the subjects was higher in the JMS-ABPM cohort than in the other cohorts (all $P < 0.01$). Diabetes was more frequent in the Ohasama sample ($P < 0.001$) compared with each of the others, but information was not available from the NYPEAP cohort. Office SBP and PP were highest in the JMS-ABPM cohort ($P < 0.01$ versus the other cohorts), whereas office DBP was highest in the PIUMA cohort ($P < 0.01$ versus the other cohorts). Comparable differences between the cohorts were found for awake and asleep ambulatory BP.

Differences Between Groups

Age of the subjects (Table 2) was higher in the WCH group than in the other groups. Subjects with WCH tended to be women more frequently, smokers less frequently, and diabetics more frequently when compared with those with ambulatory hypertension (all $P < 0.01$). In the WCH group, office BP was intermediate between the normotensive group and that with ambulatory hypertension. In contrast, awake SBP and DBP were lower in the group with WCH than in the normotensive group (both $P < 0.01$), whereas sleep SBP and DBP were comparable

between the 2 group. Prevalence of subjects treated with anti-hypertensive drugs resulting from the last telephone contact or clinical visit during follow-up is reported in Figure 1. A similar proportion of subjects included in the normotensive control group or the WCH group at entry were receiving the 5 classes of antihypertensive drugs (all $P < NS$). In contrast, a greater proportion of subjects belonging to the AH group were receiving diuretics, β -blockers, angiotensin-converting enzyme inhibitors or calcium antagonists ($P < 0.01$ versus each of the other groups). Frequency of treatment with angiotensin II antagonists did not differ between the groups.




Figure 1. Percentage of subjects treated with antihypertensive drugs resulting from the last telephone contact or clinical visit during follow-up. ACE indicates angiotensin-converting enzyme.

TABLE 3. Entry Characteristics of Subjects With and Without Future Stroke

Variable	No Future Stroke (n=5742)	Future Stroke (n=213)	P-Value
Age, years	55 (14)	68 (12)	0.0001
Sex, % men	49.3	56.3	0.04
Weight, kg	68 (16)	64 (16)	0.0001
Body mass index, kg/m ²	25.3 (3.8)	25.0 (4.0)	0.19
Diabetes, %	10.5	23.5	0.0001
Asian ethnic group, %	33.5	53.5	0.0001
Cigarette smoking, %	19.3	29.7	0.0001
Total cholesterol, mmol/L	5.43 (1.08)	5.35 (1.06)	0.293
Serum creatinine, mmol/L	86.9 (22)	91.1 (20)	0.028
Serum glucose, mmol/L	5.50 (1.3)	5.78 (1.8)	0.021
Office SBP, mm Hg	148 (22)	159 (24)	0.0001
Office DBP, mm Hg	90 (14)	90 (14)	0.95
Office PP, mm Hg	59 (16)	69 (19)	0.0001
Awake SBP, mm Hg	139 (17)	149 (19)	0.0001
Awake DBP, mm Hg	87 (15)	87 (12)	0.657
Awake PP, mm Hg	52 (15)	61 (14)	0.0001
Sleep SBP, mm Hg	121 (17)	134 (21)	0.0001
Sleep DBP, mm Hg	72 (11)	76 (12)	0.0001
Sleep PP, mm Hg	49 (11)	58 (14)	0.0001

Incidence of Stroke

There were 213 new cases of stroke. Overall, the JMS-ABPM cohort showed the highest rate of stroke (6.09×100 person years) followed by the Ohasama cohort (2.12×100 person years), the PIUMA cohort (0.59×100 person years), and the NYPEAP cohort (0.19×100 person years).

At entry (Table 3), subjects with future stroke were older, leaner, and more frequently smokers, diabetics, and of Asian ethnic origin than the subjects without future stroke (all $P < 0.01$). Office and awake SBP and PP, but not DBP, were higher in the group with future stroke than in that without future stroke (all $P < 0.001$). Sleep SBP, DBP, and PP were higher in the group with future stroke (all $P < 0.001$).

The cumulative hazard for stroke (Figure 2) differed between




Figure 2. Cumulative hazard for stroke in the 3 groups (normotensive subjects, WCH, and ambulatory hypertension).

the normotensive group, the group with WCH, and the group with ambulatory hypertension (log-rank test; P value for trend=0.0013). Figure 2 shows that the cumulative hazard for stroke was comparable in the WCH and normotensive groups up to the sixth year of follow-up. However, subsequently, there was an increase in the hazard of stroke in the WCH group, with the corresponding curve diverging from that of the normotensive group and crossing that of the ambulatory hypertension group by the ninth year of follow-up.

The crude rate of stroke ($\times 100$ person years) during the entire follow-up period was 0.35 in the normotensive group, 0.59 in the WCH group, and 0.65 in the group with ambulatory hypertension. The corresponding values up to the sixth year of follow-up were 1.06 in the normotensive group, 0.91 in the WCH group, and 1.5 in the ambulatory hypertension group. The unadjusted hazard ratios for stroke, with 95% confidence intervals (CIs), are displayed in Figure 3. Results were comparable using the 130/80 and the 135/85 mm Hg threshold values for definition of WCH.

Multivariate Analysis

In a Cox analysis (Table 4) stratified by center, WCH was associated with a nonsignificant 1.15 hazard ratio for stroke compared with the normotensive group ($P=0.658$). The no-interaction assumption of the stratified model was evaluated according to Kleinbaum¹⁷ and found acceptable at the <0.01 level. The no-interaction assumption implies that the variables being stratified (ie, center) do not interact with the covariates in the model. When office SBP and awake SBP were forced in the same model, office BP did not yield statistical significance ($P=0.322$), and the risk of stroke increased by 2% for any 1 mm Hg increase in the awake SBP (95% CI, 1% to 3%; $P=0.0001$). The 6-year risk factor-adjusted probability of stroke in clinically normotensive individuals and in hypertensive subjects with WCH and ambulatory hypertension is depicted in Figure 4. Estimates have been made in smokers and nonsmokers for either sex.

Discussion

This study is the first to investigate the short- and long-term risk of stroke in subjects with WCH, ambulatory hypertension, and clinical normotension in a large multinational and multiethnic population. WCH was defined by an average daytime ambulatory BP <130 mm Hg SBP and <80 mm Hg DBP because in a previous analysis,⁵ the risk of cardiovascular events increased in association with higher ambulatory BP levels. Average daytime levels of BP $<130/80$ mm Hg have been defined as definitely normotensive.¹⁴

During the entire follow-up period, the incidence of stroke did not differ between the WCH and the normotensive control groups. However, stroke rate showed a trend to increase after the sixth year of follow-up in the group with WCH, and the corresponding hazard curve crossed that of the ambulatory hypertension group by the ninth year of observation. Results were consistent among the different cohorts and were independent of age, sex, cigarette smoking, and previous antihypertensive medications.




Figure 3. Unadjusted hazard for stroke in the WCH and ambulatory hypertension groups compared with the normotensive group. WCH has been defined by an average awake ambulatory BP <130/80 mm Hg (left panel) or <135/85 mm Hg (right panel).

Clinical Relevance and Prognostic Value of WCH

ABPM has been approved by the US Centers for Medicare and Medicaid Services¹⁸ for reimbursement in patients with suspected WCH. Although some outcome-based studies suggested that WCH is associated with a risk of events apparently comparable to that of clinically normotensive subjects and inferior to that of subjects with elevated daytime BP,⁵⁻⁹ other studies focused on target organ damage suggested that patients with WCH may be at intermediate risk between the clinically normotensive individuals and those with ambulatory hypertension.^{7,8,19-21} Therefore, the important issue of whether WCH should be considered an innocent condition remains open and unresolved.^{4,22} Unfortunately, only a few data are available on the long-term natural history of WCH. In a longitudinal study, such condition evolved into ambulatory hypertension in 37% of subjects, with an accompanying rise in left ventricular mass.²³ In a study, a comparable proportion of subjects with clinical normotension and WCH evolved toward ambulatory hypertension (15% and 22%, respectively).²⁴

In this study, based on 38 100 person years of observation, the highest stroke rate was noted in the clinical-based JMS-ABPM cohort, which included elderly Japanese subjects with hypertension, followed by the Ohasama cohort, which included a general Japanese population, and the PIUMA cohort, which included Italian subjects with essential hyper-




Figure 4. Six-year risk factor adjusted probability of stroke in clinically normotensive subjects and in hypertensive subjects with WCH and ambulatory hypertension. Estimates have been made in smokers and nonsmokers for either sex.

tension. The lowest stroke rate was observed in the NYPEAP cohort, recruited in the New York area. In the absence of a significant center-covariate interaction, our findings can be reliably assumed as consistent across the different cohorts.

An unexpected finding in our study was a distinct trend toward an increased incidence of stroke in the WCH group after the sixth year of follow-up. Although substantiated only by a small number of events, these findings raise some concerns about the long-term safety of WCH. Clearly, further long-term studies are needed to clarify this aspect. In this context, it has been noted that the degree of BP rise during mental stress is a predictor of the long-term growth of atherosclerotic plaque independently of age and initial plaque area.²⁵ Thus, it could be speculated that frequent BP peaks triggered by alerting reactions to stress may contribute to the rise in long-term risk of carotid atherosclerosis and ultimately of stroke in subjects with WCH.

Study Limitations

Because office and ambulatory BP measurements have been obtained only at entry, no information is available on the prognostic impact of serial changes in these parameters over time. In the Office versus Ambulatory Blood Pressure (OvA) study, in-treatment ambulatory BP predicted cardiovascular events independently of traditional risk factors in treated hypertensive patients.²⁶ However, the OvA study could not compare the predictive value of pretreatment versus in-treatment BP. In the PIUMA study, in-treatment ambulatory BP was more potent

TABLE 4. Independent Predictors of Stroke

Covariate	Comparison	Hazard Ratio	P-Value	95% CI
Age	1 year	1.08	0.000	1.07-1.10
Sex	Men vs women	1.57	0.003	1.17-2.12
Smoking status	Yes vs no	1.71	0.001	1.24-2.37
Previous antihypertensive treatment	Yes vs no	1.63	0.001	1.23-2.18
Ambulatory BP category	Normotensive group	1		
	WCH	1.15	0.658	0.61-2.16
	Ambulatory hypertension	2.01	0.001	1.31-3.08

Analysis stratified by center. WCH was defined by an average awake BP <130 mm Hg SBP and 80 mm Hg DBP.

than pretreatment ambulatory BP for cardiovascular risk stratification.²⁷ In the present study, a comparable number of subjects who were clinically normotensive or white-coat hypertensives at entry were receiving antihypertensive drugs during follow-up. These data suggest a comparable evolution toward the need of antihypertensive treatment in subjects with WCH and clinically normotensive controls. Finally, because data on mortality shortly after stroke were not available from all cohorts, no separate analysis could be performed on fatal and nonfatal stroke. Similarly, analyses on the different types of stroke (ie, lacunar, embolic, hemorrhagic, etc) were not possible because of insufficient standardization across the different cohorts. A substantial proportion of strokes in hypertensive subjects are attributable to lacunar infarction at the base of the brain, where short straight arteries transmit a substantial BP load from the large arteries to small resistance arteries over a very short distance.²⁸

Perspectives

The long-term prognostic impact of WCH remains uncertain. In this multinational outcome-based study, we failed to detect differences in the risk of stroke between subjects with WCH and clinically normotensive controls. The risk of stroke remained consistently higher among subjects with ambulatory hypertension. However, the incidence of stroke showed a trend to increase in the long run in the group with WCH, with the corresponding hazard curve crossing that of the ambulatory hypertension group by the ninth year of follow-up. These data raise the hypothesis, to be tested in future studies, that WCH might not be a benign condition for stroke in the long term.

Acknowledgments

This work was supported by grants from the National Heart, Lung, and Blood Institute, Japan Arteriosclerosis Prevention Fund, and the Ministry of Japan, Associazione Umbra Cuore e Ipertensione and Bristol-Myers Squibb Company. We thank Francesca Saveri for secretarial assistance and Mariano Cecchetti for nursing assistance.

References

- Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white-coat hypertension? *J Am Med Assoc.* 1988;259:225-228.
- White WB, Schulman P, McCabe EJ, Dey HM. Average daily blood pressure, not office pressure, determines cardiac function in patients with hypertension. *J Am Med Assoc.* 1989;261:873-877.
- Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. *J Hypertens.* 1999;17:151-183.
- Verdecchia P, O'Brien E, Pickering T, Staessen JA, Parati G, Myers M, Palatini P; European Society of Hypertension Working Group on Blood Pressure Monitoring. When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. *Am J Hypertens.* 2003;16:87-91.
- Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C. White-coat hypertension. *Lancet.* 1996;348:1444-1445.
- Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshida S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *J Am Coll Cardiol.* 2001;38:238-245.
- Owens PE, Lyons SP, Rodriguez SA, O'Brien ET. Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ changes? *J Hum Hypertens.* 1998;12:743-748.
- Owens P, Atkins N, O'Brien E. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. *Hypertension.* 1999;34:267-262.
- Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, de Leeuw PW, Dobovisek J, Jaaskivi M, Leonetti G, O'Brien E, Palatini P, Parati G, Rodicio JL, Vanhanen H, Webster J. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Circulation.* 2000;102:1139-1144.
- Pickering TG, James GD. Ambulatory blood pressure and prognosis. *J Hypertens.* 1994;12(suppl 8):S29-S34.
- Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi J, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. *Hypertension.* 1994;24:793-801.
- Ohkubo T, Hozawa A, Nagai K, Kikuya M, Tsuji I, Ito S, Satoh H, Hisamichi S, Imai Y. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. *J Hypertens.* 2000;18:847-854.
- Kario K, Pickering TG, Umeda Y, Hoshida S, Hoshida Y, Morinari M, Murata M, Kuwoda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation.* 2003;107:1401-1406.
- Pickering TG, Coats A, Mallion JM, Mancina G, Verdecchia P. Task force V: white-coat hypertension. *Blood Press Monit.* 1999;4:333-341.
- Pickering TG for an American Society of Hypertension Ad Hoc Panel. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. *Am J Hypertens.* 1995;9:1-11.
- Cox DR. Regression models and life-tables. *J R Stat Soc B.* 1972;34:187-220.
- Kleinbaum DG. *Survival Analysis.* New York, NY: Springer Verlag; 1996.
- CMS. Centers for Medicare and Medicaid Services. Medicare Coverage Policy—Decisions. Ambulatory blood pressure monitoring (#CAG-00067N). 2001. <http://www.hcfa.gov/coverage/Sb3-ff.htm>.
- Grandi AM, Broggi R, Colombo S, Santillo R, Imperiale D, Bertolini A, Guasti L, Venco A. Left ventricular changes in isolated office hypertension. A blood pressure-matched comparison with normotension and sustained hypertension. *Arch Intern Med.* 2001;161:2677-2681.
- Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancina G. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). *Circulation.* 2001;104:1385-1392.
- Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata G, Pessina AC. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. *Hypertension.* 1998;31:57-63.
- Moser M. White-coat hypertension—to treat or not to treat. A clinical dilemma. *Arch Intern Med.* 2001;161:2055-2056.
- Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Sacchi N, Guerrieri M, Comparato E, Porcellati C. Identification of subjects with white-coat hypertension and persistently normal ambulatory blood pressure. *Blood Press Monit.* 1996;1:217-222.
- Polonia JJ, Santos AR, Gama GM, Basto F, Bettencourt PM, Martins LR. Follow-up clinic and ambulatory blood pressure in untreated white-coat hypertensive patients (evaluation after 2-5 years). *Blood Press Monit.* 1997;2:289-295.
- Barnett PA, Spence JD, Mamuck SB, Jennings JR. Psychological stress and the progression of carotid artery disease. *J Hypertens.* 1997;15:49-55.
- Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E; Office Versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. *N Engl J Med.* 2003;348:2407-2415.
- Verdecchia P, Reboldi G, Porcellati C, Schillaci G, Pede S, Bentivoglio M, Angeli F, Norgioli S, Ambrosio A. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. *J Am Coll Cardiol.* 2002;39:878-885.
- Spence JD. Cerebral consequences of hypertension. In: Laragh JH, Branner BM, eds. *Hypertension: Pathophysiology, Diagnosis and Management.* 2nd ed. New York, NY: Raven Press; 1995:741-753.

Time for Focus on Morning Hypertension: Pitfall of Current Antihypertensive Medication

Kazuomi Kario

It is well-known that cardiovascular events occur more frequently in the morning.¹ The ambulatory blood pressure (BP) level also increases during the period from night to early morning, and changes with various psychologic and physical stress conditions.²⁻⁴ Moreover, in the early morning, other cardiovascular risks such as thrombophilic tendencies and endothelial dysfunction are potentiated. Thus, the effect of high BP on cardiovascular risk is greater in the morning than during the other periods of the day. Theoretically, there are two types of morning hypertension (Fig. 1). The nondipper/riser (nocturnal hypertension) type, with persistent high BP from night-time to morning, is well-known to be associated with risk for damage to all target organs (brain, heart, and kidneys) and cardiovascular events.⁵ The other type, the morning BP surge type, is associated in part with the extreme-dipping status of nocturnal BP, which we have previously reported to be associated with stroke risk.⁶

Morning BP surge is one of the components of diurnal BP variation, and it could be considered to be the ambulatory BP variability during "morning" stress.⁷ Excessive morning BP surge seems to be an independent risk for cardiovascular disease, particularly in older hypertensives with impaired autoregulation of hypertensive target organs. There have been two relatively small prospective studies supporting the possible risk of morning BP surge. One was our Jichi Medical School ABPM Study (Wave 1) on 519 older hypertensive patients,⁸ in which we conducted 24-h ambulatory BP monitoring at baseline, and prospectively studied the prognosis for stroke during the follow-up period of 41 months. We defined the morning BP surge as the morning BP (the average of 2 h after arising) minus the night-time lowest BP (the average of the three BP). Because moderate morning BP surge is a physiologic phenomenon, we consider that excessive morning BP surge is a risk for cardiovascular disease. We classified the hypertensive patients studied into a morning surge group and a nonsurge group, using a cutoff value of 55

mm Hg (top 10th percentile of morning surge in systolic BP). When we identified one or more nonsurge subjects who could be matched for age and 24-h systolic BP level to one morning surge subject, and weighted the controls to simulate a balanced design, clinical stroke events occurred more frequently during the follow-up period in the morning surge group than in the nonsurge group. In this study, silent cerebral infarcts detected by brain magnetic resonance imaging were more common in the former group. In our recent study,⁹ multiple silent cerebral infarcts in the older hypertensives were significantly associated with α -adrenergic morning BP surge (defined by the reduction of the morning BP surge by an α -blocker).

Another recent French prospective study on 507 hypertensive patients also found results similar to ours.¹⁰ They used the waking BP surge, defined as the morning systolic BP measured in a standing position minus the systolic BP before rising, and divided the hypertensive patients into quartiles of waking surge. Although there were no significant differences in the 24-h BP levels among each group, left ventricular hypertrophy assessed by echocardiography at baseline was more advanced and cardiovascular complications during the follow-up period occurred more frequently in the higher quartile groups. In the multivariate analysis, waking morning BP surge was significantly associated with cardiovascular risk independently of age and 24-h BP level.

In a recent unique study in which ABPM was conducted for 7 days in a community-dwelling population, Murakami et al¹¹ found significant variation of morning BP and daytime BP during the week, whereas there was no significant difference in the night-time BP among the days of the week. Morning BP level and morning BP surge were highest on Monday, compared to those on the other days of the week. This "Monday morning surge" may contribute to cardiovascular risk, which is highest on Monday. It is well-known that cardiovascular events occur most frequently on Monday.¹²

There has been no conclusive study on the associa-

Received August 30, 2004. First decision September 4, 2004. Accepted September 8, 2004.

From the Division of Cardiology, Department of Medicine, Jichi Medical School, Tochigi, Japan.

Address correspondence and reprint requests to Dr. Kazuomi Kario, Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical School, 3311-1, Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498 Japan; e-mail: kkario@jichi.ac.jp




FIG. 1 Morning hypertension and diurnal blood pressure variation.

tion between diurnal BP variation and the onset time of cardiovascular events. However, the morning BP surge group had a higher incidence of stroke events in the morning than the nonsurge group, in our study on elderly hypertensive patients.⁸ In addition, there is a possibility that diurnal variation of onset time of cardiovascular events may be nonexistent in nondippers. In depressive patients, nocturnal onset of acute myocardial infarction is significantly more common,¹³ and diabetic patients exhibited less significant diurnal variation of onset time of acute myocardial infarction.¹⁴ Subclinical depression, a newly recognized cardiovascular risk factor, is associated with poor sleep quality. In our recent study, we found that depression in men is associated with a disrupted diurnal BP variation (a tendency to the nondipping pattern) that is independent of changes in physical activity.¹⁵

Once-daily antihypertensive drugs are now widely used, however, in medicated hypertensives, even those whose clinic BP is well-controlled; the morning BP level before taking medicine is frequently high.¹⁶ Therefore, morning hypertension is the blind spot in the current clinical practice for hypertension. Self-measured home BP monitoring and more specific management targeting morning hypertension^{17–20} will achieve a more beneficial cardiovascular outcome in hypertensive patients.

References

- Muller JE, Tofler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. *Circulation* 1989;79:733–743.
- White WB: Relevance of blood pressure variation in the circadian onset of cardiovascular events. *J Hypertens* 2003;21(Suppl 6):S9–S15.
- Kario K, Schwartz JE, Gerin W, Robayo N, Maceo E, Pickering TG: Psychological and physical stress-induced cardiovascular reactivity and diurnal blood pressure variation in women with different work shifts. *Hypertens Res* 2002;25:543–551.
- Kario K, James GD, Marion R, Ahmed M, Pickering TG: The influence of work- and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women. *Hypertens Res* 2002;25:499–506.
- Kario K, Shimada K, Pickering TG: Abnormal nocturnal blood pressure falls in elderly hypertension: clinical significance and determinants. *J Cardiovasc Pharmacol* 2003;41(Suppl):S61–S66.
- Kario K, Pickering TG, Matsuo T, Hoshida S, Schwartz JE, Shimada K: Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. *Hypertension* 2001;38:852–857.
- Kario K. Blood pressure variability in hypertension. A possible cardiovascular risk factor. *Am J Hypertens* 2004 (in press).
- Kario K, Pickering TG, Umeda Y, Hoshida S, Hoshida Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation* 2003;107:1401–1406.
- Kario K, Pickering TG, Hoshida S, Eguchi K, Ishikawa J, Morinari M, Hoshida Y, Shimada K: Morning blood pressure surge and hypertensive cerebrovascular disease: role of the alpha adrenergic sympathetic nervous system. *Am J Hypertens* 2004;17:668–675.
- Gosse P, Lasserre R, Minifie C, Lemetayer P, Clementy J: Blood pressure surge on rising. *J Hypertens* 2004;22:1113–1118.
- Murakami S, Otsuka K, Kubo Y, Shinagawa M, Yamanaka T, Ohkawa S, Kitaura Y: Repeated ambulatory monitoring reveals a Monday morning surge in blood pressure in a community-dwelling population. *Am J Hypertens* 2004 (in press).
- Amtz HR, Willich SN, Schreiber C, Bruggemann T, Stern R, Schultheiss HP: Diurnal, weekly and seasonal variation of sudden death. Population-based analysis of 24,061 consecutive cases. *Eur Heart J* 2000;21:315–320.
- Carney RM, Freedland KE, Jaffe AS: Altered circadian pattern of acute myocardial infarction in patients with depression. *Coronary Artery Dis* 1991;2:61–65.
- Rana JS, Mukamal KJ, Morgan JP, Muller JE, Mittleman MA: Circadian variation in the onset of myocardial infarction: effect of duration of diabetes. *Diabetes* 2003;52:1464–1468.
- Kario K, Schwartz JE, Davidson KW, Pickering TG: Gender differences in associations of diurnal blood pressure variation, awake physical activity and sleep quality with negative affect: The Work Site Blood Pressure Study. *Hypertension* 2001;38:997–1002.